Vivos Therapeutics is a medical technology company focused on diagnosing and treating obstructive sleep apnea (OSA). Vivos' flagship product line is its C.A.R.E. system — three proprietary oral appliances (the DNA, mRNA, and mmRNA devices) worn overnight that physically remodel the upper airway over a 9-12 month treatment course. Unlike CPAP, which requires nightly use for life, Vivos argues its devices address a root cause of OSA rather than just managing symptoms. The C.A.R.E. appliances are FDA-cleared to treat mild to severe OSA in adults, and the DNA appliance holds an exclusive FDA clearance to treat OSA in children ages 6-17. Vivos is transitioning away from a legacy model — training independent dentists (VIPs) who would prescribe and sell Vivos appliances to patients — toward directly owning or managing sleep testing and treatment centers. Under this new model, Vivos captures the full patient revenue at an average of roughly $5,000 per case, versus the wholesale economics of the legacy model. The key operational unit is a Sleep Optimization (SO) team embedded at a sleep center, which diagnoses patients, presents treatment options, and generates over $500K per month in net collections at full capacity. Vivos' most significant step in this pivot was the June 2025 acquisition of Sleep Center of Nevada, a group of seven sleep centers in Las Vegas seeing approximately 3,000 new OSA patients per month. Vivos plans to grow by acquiring additional sleep centers, entering management affiliations with existing centers using an 80/20 MSO structure, and building physician referral networks in cardiology, neurology, and pediatrics.